Bayer says FDA, EMA grant orphan drug designations for BlueRock cell therapy OpCT-001

PUBT · 2d ago
Bayer says FDA, EMA grant orphan drug designations for BlueRock cell therapy OpCT-001
  • Bayer unit BlueRock won FDA orphan drug status for lemiretprocel (OpCT-001) in primary photoreceptor diseases.
  • EMA also granted orphan designation, supporting development incentives for the investigational cell therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.